Yamauchi H, Toi M, Takayama S, Nakamura S, et al. Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or
BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer 2023 May 12. doi: 10.1007/s12282-023-01468.
PMID: 37171785